Lacosamide Stada

Lacosamide, the active ingredient in Lacosamide Stada, is an anti‑epileptic drug presented as an oral tablet for oral use. It is indicated for the treatment of partial‑onset (focal) seizures in adults and children, helping to reduce seizure frequency and improve quality of life.

GNH USA supplies Lacosamide Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality assurance protocols and regulatory standards to ensure product integrity throughout the global distribution chain.

Lacosamide is an anti‑epileptic medication used to manage seizure disorders.

Partial‑onset seizures: reduces seizure frequency in patients with focal epilepsy. Focal seizures: provides adjunctive control when monotherapy is insufficient. Adjunct therapy for epilepsy: used as an add‑on treatment in combination with other antiepileptic drugs. Refractory epilepsy: offers an alternative mechanism for patients not responding to other agents.

Lacosamide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or imbalance. - Nausea: feeling of stomach upset or urge to vomit. - Fatigue: unusual tiredness or lack of energy. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm, including PR‑interval prolongation. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Suicidal thoughts: emergence of depressive symptoms or suicidal ideation.

When prescribing Lacosamide, clinicians should consider several safety considerations. - Cardiac monitoring: assess ECG for PR‑interval changes before and during therapy. - Renal impairment: adjust dose in patients with reduced kidney function. - Concomitant CNS depressants: avoid excessive sedation when combined with alcohol or opioids. - Pregnancy: use only if potential benefit justifies potential risk, as safety data are limited. - Driving and machinery: caution patients about possible dizziness affecting ability to operate vehicles. - Store at ambient temperature: keep below 25 °C, protect from moisture and keep in original container.

Lacosamide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce Lacosamide plasma levels. - Class III anti‑arrhythmic agents (e.g., amiodarone): may increase risk of cardiac conduction abnormalities.

Moderate Interactions (Monitor Closely): - Opioids (e.g., tramadol, oxycodone): may enhance central nervous system depression. - Alcohol: concurrent use can increase dizziness and sedation. - Other antiepileptic drugs (e.g., valproate, levetiracetam): may require dose adjustments based on therapeutic response.